Table 1 Baseline data in patients with CVSS post-stenting
Items | OACs plus antiplatelet (n = 52) | Dual antiplatelet (n = 58) | p-value |
|---|---|---|---|
Demographic data | |||
 Age | 44.69 ± 12.89 | 41.38 ± 13.69 | 0.74 |
 Gender (female/male) | 39/13 | 40/18 | 0.48 |
 Mean BMI (kg/m2) | 26.20 ± 4.18 | 26.61 ± 3.98 | 0.79 |
Clinical manifestations | |||
 Headache | 34 (65.4%) | 18 (31%) | <  0.001 |
 Tinnitus | 18 (34.6%) | 11 (19%) | 0.06 |
 Visual decline | 31 (59.6%) | 36 (62.1%) | 0.79 |
 Papilledema | 34 (65.4%) | 46 (79.3%) | 0.12 |
Comorbidities | |||
 CVST | 6 (11.5%) | 3 (5.2%) | 0.22 |
 Type 2 diabetes mellitus | 3 (5.8%) | 2 (3.4%) | 0.56 |
 Hypertension | 19 (36.5%) | 13 (22.4%) | 0.10 |
 Hyperlipemia | 6 (11.5%) | 4 (6.9%) | 0.40 |
 Coronary heart disease | 2 (3.8%) | 3 (5.2%) | 0.74 |
Side of CVSS | |||
 TS | 23 (44.2%) | 29 (50%) | 0.55 |
 Superior sagittal sinus | 2 (3.8%) | 1 (1.7%) | 0.46 |
 Straight sinus | 1 (1.9%) | 1 (1.7%) | 0.94 |
 TS-SS boundary stenosis | 32 (61.5%) | 35 (60.3%) | 0.90 |